Morgan Stanley’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.02K | Sell |
914
-3,638
| -80% | -$9.52K | ﹤0.01% | 7405 |
|
|
2026
Q1 | $10.7K | Buy |
4,552
+4,239
| +1,354% | +$10.1K | ﹤0.01% | 6918 |
|
|
2025
Q4 | $729 | Sell |
313
-43,065
| -99% | -$100K | ﹤0.01% | 7435 |
|
|
2025
Q3 | $81.5K | Buy |
43,378
+34,157
| +370% | +$75.1K | ﹤0.01% | 6244 |
|
|
2025
Q2 | $26.7K | Buy |
9,221
+2,250
| +32% | +$3.24K | ﹤0.01% | 6556 |
|
|
2025
Q1 | $5.02K | Hold |
6,971
| – | – | ﹤0.01% | 6992 |
|
|
2024
Q4 | $7.18K | Hold |
6,971
| – | – | ﹤0.01% | 6905 |
|
|
2024
Q3 | $9.34K | Hold |
6,971
| – | – | ﹤0.01% | 6736 |
|
|
2024
Q2 | $9.06K | Sell |
6,971
-928
| -12% | -$1.4K | ﹤0.01% | 6711 |
|
|
2024
Q1 | $13.6K | Sell |
7,899
-16,171
| -67% | -$25.3K | ﹤0.01% | 6589 |
|
|
2023
Q4 | $35.4K | Buy |
24,070
+15,082
| +168% | +$18K | ﹤0.01% | 6474 |
|
|
2023
Q3 | $10.9K | Sell |
8,988
-542
| -6% | -$751 | ﹤0.01% | 6706 |
|
|
2023
Q2 | $13.8K | Sell |
9,530
-5,700
| -37% | -$9.76K | ﹤0.01% | 6688 |
|
|
2023
Q1 | $22.1K | Sell |
15,230
-1,847
| -11% | -$3.09K | ﹤0.01% | 6588 |
|
|
2022
Q4 | $29.5K | Sell |
17,077
-2,177
| -11% | -$4.07K | ﹤0.01% | 6523 |
|
|
2022
Q3 | $38K | Sell |
19,254
-175,177
| -90% | -$174K | ﹤0.01% | 6534 |
|
|
2022
Q2 | $144K | Buy |
194,431
+121,435
| +166% | +$353K | ﹤0.01% | 6070 |
|
|
2022
Q1 | $635K | Buy |
72,996
+22,511
| +45% | +$231K | ﹤0.01% | 5268 |
|
|
2021
Q4 | $808K | Sell |
50,485
-6,016
| -11% | -$95.5K | ﹤0.01% | 5237 |
|
|
2021
Q3 | $1.04M | Sell |
56,501
-13,271
| -19% | -$213K | ﹤0.01% | 5017 |
|
|
2021
Q2 | $974K | Sell |
69,772
-119,177
| -63% | -$1.67M | ﹤0.01% | 5095 |
|
|
2021
Q1 | $2.78M | Sell |
188,949
-82,309
| -30% | -$1.45M | ﹤0.01% | 3998 |
|
|
2020
Q4 | $5.26M | Buy |
271,258
+248,326
| +1,083% | +$3.87M | ﹤0.01% | 3202 |
|
|
2020
Q3 | $256K | Sell |
22,932
-2,838
| -11% | -$33.6K | ﹤0.01% | 4980 |
|
|
2020
Q2 | $348K | Buy |
25,770
+24,374
| +1,746% | +$274K | ﹤0.01% | 4793 |
|
|
2020
Q1 | $11K | Sell |
1,396
-15,158
| -92% | -$134K | ﹤0.01% | 5991 |
|
|
2019
Q4 | $159K | Buy |
16,554
+12,345
| +293% | +$133K | ﹤0.01% | 5497 |
|
|
2019
Q3 | $45K | Buy |
4,209
+2,717
| +182% | +$28.6K | ﹤0.01% | 5764 |
|
|
2019
Q2 | $17K | Sell |
1,492
-1,715
| -53% | -$20.6K | ﹤0.01% | 5991 |
|
|
2019
Q1 | $41K | Sell |
3,207
-23,592
| -88% | -$250K | ﹤0.01% | 5752 |
|
|
2018
Q4 | $164K | Buy |
26,799
+12,775
| +91% | +$103K | ﹤0.01% | 5361 |
|
|
2018
Q3 | $147K | Sell |
14,024
-570
| -4% | -$6.62K | ﹤0.01% | 5572 |
|
|
2018
Q2 | $214K | Buy |
14,594
+3,564
| +32% | +$45.6K | ﹤0.01% | 5507 |
|
|
2018
Q1 | $157K | Buy |
11,030
+477
| +5% | +$5.79K | ﹤0.01% | 5566 |
|
|
2017
Q4 | $124K | Buy |
+10,553
| New | +$130K | ﹤0.01% | 5579 |
|
Other funds holding SPRO
GP
P
VCM
AI
VFT
GCP
Morgan Stanley's SPRO Position: Q2 2026 in Review
Morgan Stanley reduced its Spero Therapeutics (SPRO) stake by 80% in Q2 2026, selling an estimated $9.52K and leaving 914 shares worth $2.02K. The position accounts for ﹤0.01% of the portfolio, ranked #7405.
Morgan Stanley first reported a position in SPRO in Q4 2017 and has held it in 35 quarters since. The position peaked at $5.26M in Q4 2020. 34 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.
- Morgan Stanley held 914 shares of Spero Therapeutics worth $2.02K as of Q2 2026.
- Morgan Stanley sold 3,638 Spero Therapeutics shares in Q2 2026, an estimated $9.52K.
- Spero Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7405 holding.
- Morgan Stanley first reported a position in Spero Therapeutics in Q4 2017 and has held it in 35 quarters since.
- Morgan Stanley's Spero Therapeutics position peaked at $5.26M in Q4 2020.
- 34 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.